By proceeding, you agree to our Terms of Use and Privacy Policy.
Toxicity remains the single biggest hurdle in getting ADCs to market, and drug developers are striving to develop safer antibody drug conjugates while keeping efficacy high. Although ADCs have come far, there are still more advancements to be made, highlighted by the blockbuster Enhertu and the recently approved Elahere, both containing Black Box Warnings.Created for all key stakeholders in this conversation, from pathology and toxicology to translation, nonclinical and clinical development, the ADC Toxicity Summit is the first and only event dedicated to providing case-study-led presentations and interactive discussions, enabling you to arm you with all the information you could need to maximize your therapeutic windows, from discovery to early clinical.From finding optimal in vivo and in vitro models, managing and mitigating toxicities in the clinic, to finding ideal ADC design and dosage regimes, the ADC Toxicity Summit will arm you with all you need to widen your therapeutic windows and get therapies to market faster.
Enhance the knowledge of ADC toxicity to accelerate the development of effective therapies.
Gather insights into finding optimal in-vivo and in-vitro models, managing and mitigating toxicities in the clinic, ideal ADC design and dosage regimes.
Be part of insightful panel discussions and thought-provoking keynote sessions to widen your therapeutic windows and get therapies to market faster.
Engage with top industry experts to minimize toxicities & improving tolerability to bring more ADCS with a more comprehensive therapeutic index to the market.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
AxoSim’s NerveSim® and BrainSim® platforms are revolutionizing the way that biopharmaceutical companies develop neurological drugs. Our mission is to empower advancements in human neuroscience so that patients in need can get the care they deserve. W
AxoSim’s NerveSim® and BrainSim® platforms are revolutionizing the way that biopharmaceutical companies develop neurological drugs. Our mission is to empower advancements in human neuroscience so that patients in need can get the care they deserve. We deliver human data, faster. This reduces clinica
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.